Biocon Ltd’s biopharmaceutical business did well during the March quarter, with sales rising by 46%, but contract research income grew by only 9%, pulling down overall growth to 41%. Contract research income growth is expected to improve in fiscal 2011, as a key contract is expected to see a ramp-up of operations. Though overall sales growth was still healthy, a 43% increase in material costs, and higher expenditure on power, employees and research contributed to lower profitability. Biocon’s operating profit margin declined by over a percentage point as a result. The company sees material costs being influenced by the rupee-dollar exchange rate and the product mix.
In its insulin business while growth was at 11%, during fiscal 2011 the company will be expanding to newer markets. Sales of immunosuppressants grew by 28% and will continue to drive growth in the current year as well.
In statins, Biocon expects atorvastatin sales to contribute to growth in the current fiscal. Its German acquisition AxiCorp GmbH is doing well. On the contract research front, licensing income has become a key component of profits, with the December and March quarters seeing credits of Rs18 crore and Rs21 crore, respectively.
Biocon’s profit before tax and exceptional items rose by 35% to Rs99 crore in the March quarter.
A good year of performance saw its net worth increase and debt-to-equity ratio fall to 30% from 35%. There has been a sharp improvement in its cash balance, to Rs140 crore from Rs12 crore. This will come handy as the company has outlined a sizeable capital expenditure of Rs250 crore for fiscal 2011, compared with Rs80 crore in the previous year. It also plans to spend around Rs200 crore on research and development (gross basis), compared with Rs125 crore. Part of its research expenses are shared with its partners.
At the same time, Biocon’s licensing revenue is rising. A ramp-up of its contract research business, growing portfolio of products and widening geographical presence in emerging markets should contribute to higher growth too.
Biocon is also seeking partnerships for its research programmes and if it succeeds, upfront payments will give a boost to its performance too. The outlook for 2011 looks good, contingent on its plans playing out as expected.
Friday, April 30, 2010
Biocon builds ground for growth in FY11
Industry Research Reports
LIC Term Insurance or Pvt Life Insurance Term Plan ? Which is the best term insurance in India ? Which Insurance company has the best cla...
આજકાલ કોઈપણ સમસ્યા હોય લોકો એન્ટિબાયોટિક્સ અંગ્રેજી દવાઓ લેવાનું વધુ પસંદ કરતાં હોય છે કારણ કે આજની પેઢીને આપણા જુનવાણી નુસખા વિશે જાણ હોત...
http://www.livemint.com/2007/12/13162756/SBI-UTI-MFs-to-manage-post-of.html New Delhi: Government has appointed PSU mutual funds UTI MF a...
સુરતી લોચો બનાવવાની રીત Surati Locho - સુરતી લોચો લોચો એ ગુજરાતની સૌથી સ્વાદિષ્ટ ચટપટી ખાવાની ચીજો પૈકીની એક ચીજ છે. લોચો બનાવવાની ...
i-Develop Multibagger Stock Performance last year Enter Date Exit Date Bse Code Scri...
NTPC and RIL are fighting a case in the Bombay High Court over gas pricing for the former's Kawas and Gandar power plants....
Global private equity giant The Blackstone Group has announced that it has bought a majority stake in CMS Computers Ltd. Black...
નવાઝ શરીફ સાથે મુલાકાત બપોરે પાકિસ્તાનના વડાપ્રધાન નવાઝ શરીફ અને નરેન્દ્ર મોદી વચ્ચે વાતચીત થઈ ગઈ હતી. બંને નેતાએ લગભગ 26 સેકન્ડ સુધી ...